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INTRODUCTION 
Diabetes mellitus is a syndrome of altered carbohydrate metabolism 
characterised by deficiency of endogenous insulin production or defect in 
insulin secretion or peripheral resistance to insulin action 
Mean platelet volume is one of the haematological parameters used to 
assess platelet function and activity. Large volumes correlates with increased 
platelet activity, and this in turn is associated with increased vascular 
complications in diabetes mellitus. Smaller mean platelet volumes on the 
other hand are associated with reduced platelet activity 
Conventionally, microalbuminuria, defined as daily urine albumin 
excretion of 30-300 mg. It is one of the earliest indicators of diabetic 
nephropathy. However, according to the latest KDIGO guidelines, the term 
microalbuminuria should no longer be used and urinary albumin excretion 
should instead be categorised as A1, A2 and A3, which corresponds to daily 
albumin excretion of <30 mg, 30-300 mg, and >300 mg respectively(1) 
The purpose of this study is to determine the correlation between 
platelet activity (as assessed by mean platelet volume), and diabetic 
complications, specifically diabetic nephropathy (as assessed by daily urine 
albumin excretion), and also glycaemic control (as assessed by HbA1C) 
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Glycaemic status of the patient is assessed by HbA1C levels. Patients 
are grouped into two – those with levels less than or equal to 6.5%, and those 
with levels more than 6.5%, based on ADA criteria.(2) The HbA1C is then 
compared with the mean platelet volume, to study its correlation. 
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AIMS AND OBJECTIVES 
PRIMARY OBJECTIVES 
To estimate the mean platelet volume in an uncomplicated type 2 
diabetes mellitus and to compare with normal controls 
To determine the association between mean platelet volume across 
various levels of albuminuria, thereby relating its association with vascular 
complications of diabetes, specifically diabetic nephropathy 
SECONDARY OBJECTIVES 
 To determine the association of mean platelet volume with the 
glycaemic status of the patient, as indicated by HbA1C 
 To determine the correlation between mean platelet volume and fasting 
blood glucose, post-prandial blood sugar, duration of diabetes 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW 
 Diabetes is a disease of antiquity. Ancient Egyptian texts, dating back 
to 1500 BC describe a disease with “too great emptying of the urine”. Indian 
literature from the fifth and sixth centuries BC also described the same 
disease and gave it the name “madhumeha” which means honey urine, as it 
was found that urine would attract ants 
 The first use of the word diabetes was in 250 BC, by Apollonius of 
Memphis. “Mellitus” which means honey, was added in the 1600s by 
Thomas Willis in order to differentiate the condition from diabetes insipidus, 
which also causes polyuria. 
 Sushrutha and Charaka from India in 200-500 BC, described two 
variants of the disease – one associated with young age, and the other with 
obesity. This corresponds with our current classification of type 1 and type 2 
diabetes mellitus. 
 Matthew Dobson (1735-1784) from Liverpool was the first to describe 
hyperglycaemia in a paper which he published in 1776. He collected the urine 
from his patient, Peter Dickonson, who had polyuria, and evaporated it into a 
white cake, which both smelled and tasted like sugar. The patient’s serum, 
likewise, was also found to have a sweetish taste. He therefore concluded that 
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sugar was not formed by the kidneys, but that the kidneys merely excreted 
the sugar which had previously existed in the blood 
 The scientific basis of diabetes began to be elucidated in the 18th 
century. It was Bouchardat of France who first linked diabetes and the 
pancreas together, and its associated was confirmed by Minkowski and Von 
Mering. 
DIABETES MELLITUS 
 Diabetes mellitus is a heterogeneous group of disorders that have in 
common the metabolic defect of hyperglycaemia(3). The mechanisms by 
which this hyperglycaemia is produced vary, and they may be acquired, 
genetic or environmental. This ultimately results in impaired pancreatic 
insulin secretion, impaired peripheral utilisation of glucose, and enhanced 
hepatic glucose production. 
PREVALENCE 
 Diabetes prevalence has dramatically increased over the last few 
decades. The estimated number of cases of diabetes worldwide in 2013, is 
382 million, with a projected increase to 592 million by 2035, according to 
the International Diabetes Federation (4) 
 The three countries with highest prevalence of diabetes in the world are 
India, China and US respectively (5). Approximately 80% of all diabetics 
6 
 
reside in developing countries, with India and China having the largest 
contribution (6) 
 The prevalence of diabetes according to the WHO criteria was 5.6% 
among the urban areas and 2.7% among rural areas (7) 
 Although both types of diabetes show a trend of increasing prevalence, 
the number of cases of type 2 diabetes s increasing at a much faster rate than 
the number of cases of type 2 diabetes. The reason may be due to rising 
prevalence of obesity, industrialisation of countries, resulting in decreased 
physical activity and an ageing population 
CLASSIFICATION 
There are four clinical types (8) 
•
 Type 1 – occurs due to destruction of pancreatic ß-cells, usually 
culminating in complete insulin deficiency 
•
 Type 2 – occurs due to insulin resistance and progressive defect 
in insulin secretion 
•
 Other specific types – genetic defects, disorders of exocrine 
pancreas, drug-induced 
•
 Gestational diabetes  mellitus – it is carbohydrate intolerance 
occurring during pregnancy 
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DIAGNOSIS OF DIABETES MELLITUS 
 The classic symptoms of hyperglycaemia such as polyuria, blurred 
vision, increased thirst and recent weight loss should arouse clinical suspicion 
of diabetes mellitus 
CRITERIA FOR DIAGNOSIS OF DIABETES MELLITUS (9) 
• Random blood sugar >200 mg/dL, plus symptoms of diabetes 
• Fasting blood sugar >126 mg/dL 
• HbA1C>6.5% 
• 2-hour plasma glucose >200 mg/dL after an oral glucose tolerance test 
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As the various measures of glycaemia denotes different physiological 
phenomena, they will each identify different proportions of the diabetic 
population. For instance, switching the diagnostic criteria for diabetes, from 
fasting plasma glucose to HbA1C would result in a decrease in the number of 
people diagnosed (10) 
 For example, the national health and nutrition examination survey 
(NHANES; 1999 to 2006), involve analysis of 6890 adults, with no prior 
history of diabetes. The prevalence of diabetes in this population using 
HbA1C was 2.3%, but when fasting plasma glucose was used, the prevalence 
rose to 3.6% (11) 
 Overall, both criteria, whether HbA1C or fasting blood glucose, resulted 
in 98% of the population being assigned the same classification. The 
American Diabetes Association, in 2003, recommended using fasting plasma 
glucose or a 75g oral glucose tolerance test to diagnose diabetes(12). The 
International Expert Committee in 2009, recommended the use of HbA1C 
with a value of 6.5% and above making the diagnosis of diabetes. 
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PLATELET BIOLOGY 
PLATELET: 
 Platelets are anucleated, circulating, disc-shaped cells, which are 
responsible for the initiation of haemostatic mechanisms that repair vascular 
endothelial injury. They have four major functions 
1. Platelet adherence 
2. Activation and secretion 
3. Platelet aggregation (13) 
4. Interaction with coagulation factors 
OVERVIEW OF FUNCTION: 
Whenever there is a break in the integrity of vascular endothelial 
lining, platelets come into contact with the underlying connective tissue 
matrix, especially collagen fibrils. This activates signalling pathways, which 
cause the platelet to change shape and secrete thromboxane A2 and ADP, 
which is turn stimulate neighbouring platelets, producing further activation. 
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Activating platelets also directly bind fibrinogen, via the glycoprotein 
IIb/IIIa(14, 15). A single fibrinogen molecule can bind to two GpIIb/IIIa 
receptors, thus cross-linking the platelets, producing platelet aggregation (16). 
There are at least 40,000 to 80,000 copies of GpIIb/IIIa on each platelet, thus 
very large aggregates of platelets can be assembled at the sites of platelet 
activation (17, 18). 
 Besides these mediators, other agonists can also activate platelets. 
Tissue factor is present on all non-vascular cells. Whenever there is a 
disruption of endothelium, circulating blood is exposed to this tissue factor, 
which interacts with factor VIIa, and ultimately generates thrombin, which is 
the most potent platelet agonist. Platelets expedite this process as they 
contain procoagulant phospholipids, which promote the generation of 
thrombi. Thus the process of platelet activation and deposition of fibrin are 
closely intertwined.  
PLATELET ACTIVATION: 
 Platelets may be activated by adherence to exposed collagen fibrils, or 
by exposure to circulating factors like thrombin and ADP(19) 
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SHAPE CHANGE: 
 When platelets are activated, their distinctive discoid shape is lost, and 
cytoskeletal rearrangements occurring within the platelets cause it to acquire 
an irregular morphology. There are three major cytoskeletal protein structures 
in the platelets 
1. Actin network 
2. Membrane-associated cytoskeleton 
3. Marginal band of microtubule coil 
Circulating platelets are unable to bind to fibrinogen or bind to each 
other. It is only after their activation that they are able to do so. This is 
because the platelet activation results in a change in the conformation of 
GpIIb/IIIa receptor, by a complex process known as inside-out signalling (20, 
21)
 and it is this change in the conformation of the GpIIb/IIIa which allows 
fibrinogen binding. 
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SECRETION (GRANULE EXOCYTOSIS): 
 There are three types of platelet granules 
1. Dense granules – these are platelet agonists, which promote 
platelet activation (eg. ADP, ATP, serotonin) 
2. Alpha granules – von Willebran factor, fibronectin, fibrinogen, 
vitronectin 
3. Lysosomal granules – glycosidases, proteases (22) 
Mean platelet volume serves as the index of the activating and average 
size of the circulating platelets. Platelet with larger mean platelet volume are 
younger and tend to be more reactive and aggregable. When compared to 
platelets with smaller mean platelet volume, they possess denser granules, 
produce larger amounts of thromboxane A2, and secrete increased quantities 
of serotonin, and beta thromboglobulin(23, 24, 25) 
All of these effects lead to a generalised procoagulant state. This 
results in greater thrombotic complications. There may therefore exist, a 
relationship between mean platelet volume (which is a measure of platelet 
function), and vascular complications in diabetes. Large mean platelet 
volume therefore is an indicator of the state of thrombogenesis(23, 26) 
In diabetes, rupture of atherothrombotic plaques may result in small 
haemorrhages which lead to platelet hyperreactivity, recruitment of new 
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platelets, and stimulation of bone marrow. High mean platelet volume can 
therefore be viewed as a novel risk factor(27) for the various vascular 
complications in diabetes which is now being considered a prothrombotic 
state, having increased platelet reactivity. This platelet  hyperreactivity has 
been documented  both in vivo and in vitro in diabetes (26, 28) 
 The aetiology of platelet hyperreactivity in diabetes is multifactorial (24, 
29, 30)
. Some of the reasons are biochemical, such as hyperlipidaemia, and 
hypertriglyceridaemia, and increased expression of growth factors and 
lipoprotein receptors, insulin resistance and oxidant and inflammatory state 
(24, 29, 30)
. Hyperglycaemia induces non-enzymatic glycation of various 
proteins on the platelet surface, thus increasing platelet reactivity by 
activation of protein kinase C and the osmotic effect of glucose (29, 31). This 
glycation results in a decrease in the fluidity of the platelet membrane and an 
increase in platelet activation (29, 31).  
There is also a functional insulin receptor, IR, on the platelet 
membrane, and by this mechanism insulin directly regulates platelet function. 
Experiments have revealed that insulin interferes with platelet interaction 
with collagen and reduces the pro-aggregant effects of agonists in non-obese 
healthy individuals (29, 31).  
In inflammatory states, intra-platelet release of calcium, which occurs 
during platelet activation is increased by superoxide and this increases 
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platelet activity. Superoxide also decreases the activity of nitric oxide, as 
oxidative stresses reduce the endothelial function, thus decreasing nitric 
oxide and prostacyclin production. This effect of reduced nitric oxide activity 
causes increased platelet reactivity.  
Diabetic patients have platelets that contain increased amounts of 
GpIIa receptors, and surface P-selectin. They therefore possess greater 
sensitivity to stimulation when compared to platelets taken from persons 
without diabetes(30) 
Platelet hyperreactivity is also seen in diabetics, because of 
dysregulated signalling pathways, resulted in greater aggregation and 
activation, while responding to a given stimulus. Activation of platelets plays 
an important role in the pathology of diabetes, as it triggers thrombus 
formation which in turn causes microcapillary embolization, and the relief of 
mitogenic constrictive and oxidative substances, such as vascular endothelial 
growth factor and platelet derived growth factor. These in turn result in an 
acceleration in the progress of local vascular lesions of diabetes, such as the 
neovascularisation of lens(31) 
Another cause of increased mean platelet volume in diabetes may be 
the occurrence of an atherothrombotic event such an myocardial infarction. 
This results in rapid consumption of smaller sized platelets and causes a 
compensatory increase in the generation of reticulated platelets(32, 33) 
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SCREENING FOR DIABETES 
Screening for type 2 diabetes is recommended for the following reasons 
1. Several individuals with diabetes mellitus are symptom-free and 
therefore unaware of the diagnosis 
2. Studies have shown that type 2 diabetes mellitus might already exist 
for up to 10 years prior to the diagnosis 
3. Some individuals have complications of diagnosis present at the 
time of diagnosis 
4. Treatment of type 2 diabetes may have a favourable effect on the 
natural history of the illness 
American Diabetes Association recommends that all individuals who 
are above 45 years of age should be screened for diabetes every 3 years. 
Screening should commence at an even earlier age, if they have obesity (ie. 
BMI >25 kg/m2) or other risk factors for diabetes (42) 
Unlike type 2 diabetes, where hyperglycaemia exists for a long 
asymptomatic period before the patient is diagnosed with the disease, in type 
1 diabetes, such a long latent period is rare. Therefore, despite the availability 
of several immunological markers for type 1 diabetes, they have not been 
recommended for routine clinical use 
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OVERALL REGULATION OF GLUCOSE HOMEOSTASIS: 
 Plasma glucose reflects the delicate balance between the peripheral 
glucose uptake and utilisation and the hepatic glucose production. This 
metabolic equilibrium is regulated by several components, with insulin being 
the most important one. During fasting, the decreased levels of insulin 
promotes hepatic glycogenolysis and gluconeogenesis, along with a decrease 
in the uptake of glucose by tissues that are insulin-sensitive (ie. skeletal 
muscle and fat).  
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 This promotes the mobilisation of free fatty acids (lipolysis) and amino 
acids. Furthermore, when either the blood glucose or insulin levels are 
reduced, the pancreatic alpha cells secrete glucagon, and this stimulates 
gluconeogenesis and glycogenolysis in the renal medulla and in the liver. 
 Following a meal, the post-prandial glucose elevation produces a rising 
insulin, along with a simultaneous fall in glucagon, and this results in the 
reversal of this process. The large portion of post-prandial glucose is utilised 
by skeletal muscle, due to insulin-stimulated glucose uptake 
 
REGULATION OF GLUCOSE HOMEOSTASIS 
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INSULIN BIOSYNTHESIS 
 Insulin is secreted in the islets of Langerhans by the pancreatic beta 
cells. It is initially secreted as preproinsulin, which is a single-chain 
polypeptide precursor with 86 amino acids. Subsequently, the amino-terminal 
signal peptide is removed by proteolysis, thus producing proinsulin, which 
structurally resembles the insulin-like growth factors 1 and 2. Further 
processing involves the cleavage of C-peptide residue with 31 amino acids, 
thus generating the A and B chains of insulin, that are linked by disulphide 
bonds.  
 The C-peptide is stored together with the mature insulin molecule, and 
they are both co-secreted from the beta cells. On account of larger half life of 
C-peptide, it is useful as an indicator of insulin secretion. It is also useful in 
the evaluation of hypoglycaemia, as it permits a differentiation between 
exogenous and endogenous sources of insulin secretion. 
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INSULIN BIOSYNTHESIS 
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INSULIN SECRETION 
Glucose levels greater than 70 mg/dL results in the stimulation of 
insulin synthesis. The glucose molecule is first transported by a facultative 
glucose transporter into the beta cell. Here it is phosphorylated by 
glucokinase, and enters glycolysis, thus generating ATP and this ATP 
inhibits the activity of the ATP-sensitive potassium channels.  
When this channel is inhibited, it results in a depolarisation of the 
membrane of beta cell, and this results in the opening of voltage dependent 
calcium channels, thus resulting in an influx of calcium. It is this calcium 
which ultimately stimulates insulin secretion. Furthermore, incretins are 
secreted by neuroendocrine cells in the gastrointestinal tract. Their function is 
to amplify insulin secretion, and suppress glucagon secretion.  
The most potent incretin is glucagon-like peptide 1 (GLP-1). It is 
secreted from the L-cells of the small intestine. It induces secretion of insulin 
only if the plasma glucose rises above the fasting level. 
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INSULIN SECRETION: 
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INSULIN ACTION 
 About half of total insulin which is secreted into the portal system is 
degraded by the liver. The remainder enters systemic circulation and binds to 
receptors on the target tissues. Binding to its receptor results in a stimulation 
of the intrinsic tyrosine kinase activity. This then leads to auto 
phosphorylation of receptors, and also the recruitment of various other 
intracellular second messengers, which include the insulin receptor substrate 
(IRS).  
 This results in a complex cascade of reactions involving 
phosphorylation and dephosphorylation, thus producing the widespread 
mitogenic and metabolic effects of insulin. Some of the effects include 
protein synthesis, glycogen synthesis, and lipogenesis. The expression of 
various genes are also regulated by insulin. 
 The action of insulin is regulated by three pathways that sense nutrition 
1. Hexosamine biosynthetic signalling pathway 
2. AMP-activating protein kinase signalling pathway 
3. Mammalian target of rapamycin signalling pathway 
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PATHOGENESIS 
TYPE 1 DIABETES MELLITUS  
In patient with type 1 diabetes mellitus there will be beta cell secretory 
function defect due to selective loss of cells which are responsible for the 
secretory function by autoimmune mediated response. There will be 
infiltration of pancreatic islets causing insulitis. This is primarily mediated by 
CD8+ T cells which causes destruction of specific beta cells.  
The etiology of type 1 diabetes mellitus is complex. It includes  
• Genetic predisposition 
• Environmental factors that triggers autoimmunity 
In patients with genetic susceptibility having auto antibodies  to islet 
cells various indicators such as insulin release abnormalities may predict the 
clinical onset. Based on these mechanisms various clinical trials are in 
progress which aims at stopping the autoimmune response there by halting 
the progression of disease.  
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PATHOGENESIS 
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GENETIC PREDISPOSITION  
 Multiple genes are involved in the pathogenesis of type 1 diabetic 
mellitus. In identical twins the occurrence of type 1 diabetic mellitus ranges 
from 40 to 60 %. It shows there are many other additional factors which are 
also involved in the occurrence of type 1 diabetic mellitus.  
 The major gene which is responsible for causing type 1 diabetic 
mellitus is present in chromosome 6 involving HLA complex. It encodes the 
necessary genes in the class II MHC molecule. These play a role in the 
antigen presentation to T helper cells which initiates the immune response. 
This ability of antigen presentation further depends on the aminoacid 
constituents of antigen binding sites.  
 Most of the type 1 diabetes mellitus patients consists of HLA DR3 or 
HLADR4 haplotype. Other haplotypes such as DQA10201, DQB10302 and 
DQ1310301 are also involved in the association of type 1 diabetes mellitus. 
Even though many individuals with these predisposing HLA types does not 
develop type 1 diabetes mellitus. 
 There are are various other genetic loci which are found to contribute 
to the development of type 1 diabetes mellitus. Also there are genes which 
protects against the development of type 1 diabetes mellitus. These are 
DQA101202 and  DQB10602. These haplotypes are very rare in patients with 
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type 1 diabetes mellitus and are believed to confer protection against the 
development of type 1 diabetes mellitus. 
PATHOPHYSIOLOGY 
 Even though the other cell types (such as alpha cells, delta cells, 
pancreatic polypeptide producing cells) islets of pancreas have functional and 
embryological similarity with the beta cells and almost have same protein, 
they are not involved in this autoimmune destruction. 
 Initially there will be lymphocytic infiltration of the beta cells that was 
followed by the destruction of beta cells. At a later stage the islets will 
become atrophic. Studies in the experimental models have shown that both 
humoural and cellular immunity plays a role in this autoimmune process. 
The various abnormalities that are produced during this process are  
1. Autoantibodies to islet cells 
2. Lymphocytic infiltration of islets 
3. Lymphnodes around peripancreatic area and activated lymphocytes in 
systemic circulation 
4. Cytokine release within islets 
These cytokines exert toxic effects especially to the beta cells. This 
action is mediated by nitric oxide metabolite formation apoptosis of islet beta 
cells. The destruction of beta cells is primarily T lymphocyte mediated 
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process and not because of autoantibodies to islet cells. These autoantibodies 
does not react with cell surface of islets and hence they do not transfer 
diabetes to animals.  
The various molecules of islets that are targeted by these autoimmune 
mechanisms are insulin, glutamic acid decarboxylase (the enzyme 
responsible for GABA production) and a cell specific zinc transporter 
protein. Various theories suggests that these autoimmune process initiates 
destruction of one beta cell thereby producing a series of secondary 
autoantigens that will spread and cause the destruction of other islet 
molecule.   
IMMUNOLOGIC MECHANISMS 
 The autoantibodies of islet cells comprises of various antibodies that 
target specific cell types of islets of pancreas such as insulin, znT8, GAD. 
These serve as useful markers of the autoimmune process involving type 1 
diabetes mellitus. There are various commercially available assays to 
measure the levels of these antibodies.  
 These islet cell antibody testing (ICA) is very useful in differentiating 
type 1 diabetes mellitus from other types. It also identifies the patient at risk 
for developing type 1 diabetes mellitus. These ICAs are present in majority of 
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type 1 diabetes mellitus (>85%) in some of type 2 diabetes mellitus(5-10%) 
and rarely in gestational diabetes mellitus(<5%).  
 These ICAs are also present in first degree relatives of patient with 
type 1 diabetes mellitus. A combination of ICA and glucose tolerance test 
predicts > 50% risk of developing type 1 diabetes mellitus in 5 years. 
ENVIRONMENTAL FACTORS  
 Various environmental factors are proposed in triggering the 
autoimmune process of type 1 diabetic mellitus. None has been confirmed by 
studies. These environmental factors includes  
• Viral infections (coxsackie, rubella, enterovirus, most prominently) 
• Proteins in bovine milk  
• Compounds of nitrosurea 
PREVENTION OF TYPE 1 DIABETIC MELLITUS 
 Various interventions has been proposed in experimental models for 
the prevention of type 1 diabetic mellitus, but none has been successful. 
Studies shown that IV insulin administration to at risk individuals for type 1 
diabetic mellitus does not prevent it. Various clinical investigation is going 
on these process.  
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TYPE 2 DIABETIC MELLITUS 
To develop type 2 diabetic mellitus the major mechanisms responsible are  
• Insulin resistance  
• Abnormal insulin secretion   
Even though many studies suggests that insulin resistance precedes the 
insulin secretion abnormality the diabetes become apparent only when there 
is inadequate insulin secretion. Type 2 diabetes mellitus comprises of various 
disorders that all share the phenotype of hyperglycemia.  
 Various studies suggests that south and east Asian ethnic groups 
develop diabetes at a more younger age and with a low BMI. There are 
certain group of patients with type 2 diabetes mellitus who are more prone to 
develop ketosis (often obese) and some who are ketone resistant. (often lean).  
GENETIC CONSIDERATIONS  
There is a strong genetic correlation with type 2 diabetic mellitus. The 
development of type 2 diabetes mellitus in concordant twins is between 70 
and 90 %. The children of a type 2 diabetes mellitus individual have 
increased risk of getting diabetes. If both parents affected with type 2 
diabetes mellitus then the risk arouses to 40%. Insulin resistance is present in 
many of the first degree relatives of a patient with type 2 diabetes mellitus.  
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 Diabetes mellitus is a multifactorial and polygenic disorder. It involves 
genetic susceptibility, environmental factors (physical inactivity, diet, 
obesity). The genetic predisposition to type 2 diabetic mellitus are 
incompletely understood. Still most of the studies suggest that large number 
of genes contribute to a relatively small risk for the development of type 2 
diabetic mellitus. The most important among these is a gene of transcription 
factor 7 variant.  
 The mechanisms by which these genetic alteration contributes to 
development of type 2 diabetic mellitus is still not clearly understood, but 
most of these interferes with function of islets or development of islets or 
secretory defect. The genetic susceptibility for the development of type 2 
diabetic mellitus is under active investigation. Type 2 diabetes mellitus is 
mainly characterised by  
• Impairment of insulin secretion 
• Development of insulin resistance 
• Increased gluconeogenesis from liver 
• Fat metabolism abnormalities  
Central obesity is frequently seen (>80%) in patients with type 2 
diabetic mellitus. Even though there is insulin resistance, in the initial stage 
of type 2 diabetes mellitus the glucose tolerance remains within normal limits 
because of the increased insulin production to compensate for the insulin 
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resistance. With progression in insulin resistance, there will be compensatory 
hyperinsulinemia but at one stage the pancreatic islets are unable to sustain 
the increased production of insulin.  
 With this stage there will be development of  impaired glucose 
tolerance which is characterised by increase in post prandial glucose. With 
further progression of disease, there is reduction in insulin secretion with 
increase in glucose production by the liver leading to a state of overt diabetes 
mellitus characterised by increase in fasting blood sugar. The relative 
contribution of both these processes (impaired insulin secretion and insulin 
resistance) varies from individual to individual. 
 
INSULIN RESISTANCE SYNDROMES 
 It comprises various group of disorders with hyperglycemia as a 
common component. These include  
• Metabolic syndrome 
• Insulin resistance syndrome 
• Syndrome X  
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INSULIN RESISTANCE SYNDROMES 
 It comprises various group of disorders with hyperglycemia as a 
common component. These include metabolic syndrome, the insulin 
resistance syndrome and syndrome X which shares the various metabolic 
disorders that includes hypertension, central obesity, dyslipidemia, insulin 
resistance. 
 There are various other rare forms which comprises features of 
diabetes mellitus. Acanthosis nigricans and hyperandrogenism (characterised 
by acne, hirsutism, oligomenorrhoea in women) are also associated with 
these syndromes. Two distinct syndromes involving severe insulin resistance 
have been described in adults. 
• Type A – defect in insulin signalling pathways, affects young females 
and have features of hyperandrogenism, obesity 
• Type B – due to autoantibodies to insulin receptor, affects middle aged 
females, associated with other auto immune disorders. 
Polycystic ovary syndrome is a disorder affecting premenopausal 
women with features of hyperandrogenism and chronic anovulation. Some 
group of women with PCOS have insulin resistance and increase in the risk 
of developing type 2 diabetic mellitus.  
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MONOGENIC FORMS OF DIABETES 
 There are various monogenic forms of diabetes. Various variants of 
MODY have been identified. They are caused by mutation of genes encoding 
islet enriched transcription factor. These factors have a role in interfering 
with glucose stimulated secretion of insulin. They are transmitted as 
autosomal dominant forms. The affected individuals will often have other 
defects such as liver function abnormalities, renal cysts and pancreatic 
exocrine insufficiency. 
 Neonatal diabetes (onset < 12 months of age) is caused by genetic 
mutations. It is phenotypically similar to that of type 1 diabetes mellitus. The 
major mutations involved are  
• ATP sensitive potassium channel subunits (kir 6.2 and ABCC8) 
• Insulin gene defects 
These individuals may be treated with sulfonylurea and usually 
respond well. 
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HETEROGENEOUS ETIOLOGY OF YOUNG ONSET DIABETES 
 
 
 
 
 
 
 
 
 
41 
 
 
COMPLICATIONS 
 Diabetes affects various organ systems leading to various 
complications. They include microvascular, macro vascular and nonvascular 
complications. The microvascular complications are retinopathy, neuropathy 
and nephropathy. Macro vascular complications are coronary heart disease, 
peripheral vascular disease, and cerebrovascular disease.  
 The various non vascular complications are gastroparesis, infections, 
hearing loss and skin abnormalities. 
DIABETIC NEPHROPATHY 
 In our study we are correlating the mean platelet volume and the 
albuminuria levels in diabetic patients there by studying role of mean platelet 
volume in the development of vascular complications specifically diabetic 
nephropathy. High albuminuria (previously microalbuminuria)is an early 
indicator of diabetic nephropathy. 
 Diabetic nephropathy is the most important cause of chronic kidney 
disease and end stage renal disease. Albuminuria in diabetic individuals is 
also associated with an increased risk of cardiovascular disease. Usually the 
diabetic patients with diabetic nephropathy have associated diabetic 
retinopathy. 
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PATHOGENESIS 
 Due to chronic hyperglycemia there will be activation of soluble 
factors (growth factors, endothelin, angiotensin II, advanced glycation end 
products) alteration in the microcirculation of kidney (hyperfiltration, 
increased glomerular capillary pressure) and glomerular structural 
changes(mesangial expansion, fibrosis, thickening of basement membrane) 
 Initially during the first few years of diabetes mellitus there will be 
glomerular hyperperfusion, renal hypertrophy and thickening of glomerular 
basement membrane. Later after some 5 to 10 years individuals will began to 
loss small amounts of albumin in urine.  
The KDIGO and ADA proposed in recent years that the 
microalbuminuria (30-299 mg/dl) and macro-albuminuria (>300mg/dl) 
should be replaced by high albuminuria and persistent albuminuria 
respectively as they better the continuous nature of urine albumin excretion 
and are risk factors for the development of diabetic nephropathy and 
cardiovascular disease. 
This albuminuria levels should be detected at an early stage, as 
effective pharmacological therapy during this stage can delay the progression 
of diabetic nephropathy. Micro albuminuria levels should be assessed 
annually in patients with type 1 and type 2 diabetes mellitus. In patient with 
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type 1 diabetes mellitus screening for microalbuminuria should begin 5 years 
after diagnosis and in type 2 patients at the time of diagnosis. 
Improvement in glycaemic control and use of ACE inhibitors or 
ARB’s can reduce the albuminuria levels and also reduces intra glomerular 
pressure thereby delaying the progression of diabetic nephropathy. 
MICROALBUMINURIA 
Quantifying urine excretion of albumin is more sensitive than 
measuring general proteinuria. Albumin is normally excreted at a rate of <30 
mg/day. When albumin excretion is persistently between 30-300 mg it is 
known as high albuminuria (previously known as microalbuminuria). When 
excretion exceeds 300 mg/day, it represents overt or dipstick positive 
proteinuria, and is known as very high albuminuria (previously known as 
macroalbuminuria). 
In the case of type 1 diabetes, high albuminuria (previously 
microalbuminuria) might represent the earliest clinical manifestation of 
diabetic nephropathy, and usually begins to be seen five years after diagnosis. 
On the other hand, patients with type 2 diabetes, usually have high 
albuminuria at the time of diagnosis and this albuminuria probably represents 
underlying cardiovascular disease and not diabetic nephropathy in particular, 
as is the case in type 1 diabetes. 
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It is recommended that screening for high albuminuria be done at 
yearly intervals, in patients with both types of diabetes, starting at disease 
onset in type 2 diabetes, and five years after the disease onset in type 1 
diabetes. While diagnosing high albuminuria, conditions causing transient 
elevation in albumin excretion should be excluded(34). 
Such conditions include 
• Exercise 
• Fever 
• Infection 
• Poor glycaemic control 
• Hyperlipidaemia 
• Elevated blood pressure 
URINE ALBUMIN CONCENTRATION 
 The gold standard for diagnosing high albuminuria is 24-hour urine 
collection. However, screening can be more easily achieved using an early-
morning specimen, or a timed urine collection, in order to minimise urinary 
volume changes which occur during the day(34). If the rate of albumin 
excretion in a timed urine collection is below 20 µg/min, or if the 
concentration of urine albumin in a random specimen is less than 20-30 
mg/L, high albuminuria is unlikely. 
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 Higher values, especially values just above these ranges could 
represent false positivity, and therefore, such samples need to be confirmed 
by repeating the measurement. Semiquantitative dipsticks are also available, 
which can detect high albuminuria in situations where a direct measurement 
of urine albumin excretion cannot be obtained.  
The disadvantage of using urine albumin concentration or dipstick 
tests, is that false results may occur because urine albumin concentration 
depends not only on the amount of albuminuria, but also on the urine 
volume(35). Thus, even if the rate of urine albumin excretion is constant, there 
may be a change in the urine albumin concentration if there occur substantial 
changes in urine volume. This confounding factor may be eliminated by 
performing repetitive measurements on early morning samples.  
ALBUMIN-CREATININE RATIO 
 Measurement of urine albumin-to-creatinine ratio in a random sample 
of urine removes the confounding effect of urine volume on concentration of 
urinary albumin. Values of 30-300 mg/g of creatinine imply daily albumin 
excretion levels of 30-300 mg/day, corresponding to high albuminuria 
(previously microalbuminuria)(36). 
 Urinary albumin-creatinine ratio >300 mg/g of creatinine indicates 
very high albuminuria (previously macroalbuminuria). However, at least two 
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out of three specimens should have ACR levels without the high or very high 
ranges to make the diagnosis in order to eliminate false positives(36) 
 In one study, spot urine albumin-creatinine ratio and 24-hour urine 
collection were used to quantify urine albumin excretion. The study involved 
13 individuals with type 1 diabetes, 12 individuals with type 2 diabetes, and 
14 normal subjects(37). Both measurements were found to give similar results. 
The presence of ACR more than 30 mg/g was 100% sensitive in detecting 
high albuminuria. These findings have been confirmed by the other studies as 
well(38). 
LIMITATIONS OF URINARY ACR 
 Patients must be instructed to avoid vigorous exercise for 24 hours 
prior to being tested, as this can transiently raise the urinary albumin 
excretion(39). Uncertainty exists regarding the optimal time to perform urine 
albumin-creatinine ratio. In one study, the highest correlation between urine 
ACR and 24-hour urine collection was seen when samples were taken after 
the first morning void and last sample before the bedtime(40). However, a 
more large scale study, performed later, revealed a better correlation when 
first morning void was used. However, in this study, the differences which 
were noted with samples collected at other times were not found to be 
significant(41). The test had reduced accuracy if excretion of creatinine is 
greatly different from expected values, especially when patients had 
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borderline values. The ratio will be reduced in muscular individuals because 
of high urinary creatinine excretion, and the ratio will be increased in 
emaciated individuals, where muscle mass and therefore urinary creatinine 
excretion, are significantly reduced. 
DIABETIC RETINOPATHY 
It comprises two stages. 
• Non proliferative stage 
• Proliferative stage 
Non proliferative stage is characterised by microaneurysms, blot 
haemorrhage and cotton wool spots. Proliferative retinopathy is characterised 
by neovascularisation of retina which occurs due to retinal hypoxia. These 
new vessels are very fragile and rupture easily causing vitreous haemorrhage, 
fibrosis and culminating in retinal detachment. 
Regular ophthalmic examination is necessary in all patients with type 2 
diabetes mellitus to prevent diabetic retinopathy. Laser photocoagulation will 
be useful in later stages. 
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DIABETIC RETINOPATHY 
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DIABETIC NEUROPATHY 
 Various manifestations such as mononeuropathy, polyneuropathy and 
autonomic neuropathy can occur. Distal symmetric polyneuropathy is the 
most common form. Paresthesia or hyperaesthesia may occur. Usually pain 
presents at rest and worsens at night. Polyradiculopathy is characterised by 
involvement of one or more nerve root.  
VARIOUS COMPLICATIONS OF DIABETES 
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MONITORING DIABETES 
 The most important goal in diabetes management is to attain normal 
physiological levels of glucose without leading to hypoglycaemia.(42) The two 
most commonly used glycaemic measures are blood glucose and HbA1c 
(glycated haemoglobin).  
HbA1c levels indicatesthe overall glycaemic control in the previous 8 -
10 weeks thereby assessing the therapeutic response. While the blood glucose 
levels gives information about day to day control levels and subjected to wide 
variation other than fasting blood glucose. 
The haemoglobin present in the blood combines with glucose non 
enzymatically to form glycated derivatives. This glycation reaction in turn 
depends on the concentration of glucose in the blood. This reaction occurs 
between beta chain of haemoglobin A molecule and glucose forming HbA1c. 
It is now widely used as a standard measurement to monitor glycaemic 
control. 
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TREATMENT OF DIABETES MELLITUS 
 Life style modification such as healthy diet, increased physical activity 
plays an important role in diabetes management. Insulin is recommended in 
all patients with type 1 diabetes mellitus and also useful in type 2 diabetes 
mellitus. The patient should be encouraged to self-monitorthe blood glucose 
levels there by preventing hypoglycaemia related complications. 
 All measures should be taken to prevent diabetic complications by 
routine screening for complications. The associated diseases like 
hypertension and dyslipidaemia should be addressed. There are various 
antidiabetic drugs available and the choice of one depends on the blood sugar 
levels and patient condition. Combination of drugs can be used if the patient 
is having severe hyperglycaemia.  
 The most dangerous complication of therapy with diabetes is 
hypoglycemia. Weight gain is another adverse effect. Recurrent 
hypoglycemia necessitates modification of treatment regimen and glycaemic 
control for the patient. 
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TREATMENT OF DIABETES MELLITUS 
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EMERGING THERAPIES  
 Pancreas transplantation is an important option in patients with type 1 
diabetic mellitus with end stage renal disease. But immunosuppression is 
needed. Newer pharmacological therapies includes glucokinase activators, 
GPR40 agonists, monoclonal antibodies to inflammation and 11 beta 
hydroxysteroid dehydrogenase inhibitors for type 2 diabetes mellitus patients. 
 Bariatric surgery has been recommended in obese individuals with type 
2 diabetes mellitus. ADA recommends bariatric surgery in type 2 diabetes 
individuals with Body Mass Index > 35 kg /m2.  
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MATERIALS AND METHODS 
PATIENT SELECTION  
 All patients were explained about the diabetes and its complications. 
They were informed about the study proceedings and the usefulness of the 
study in their own language. All the subjects gave consent before 
participating in the study.  
DESIGN OF THE STUDY 
 Cross sectional study 
STUDY CENTRE 
 Institute of internal medicine and  
 Institute of diabetology 
 Madras medical college and Rajiv Gandhi government general 
hospital, Chennai 
STUDY DURATION  
 April 2015 to September 2015 – total 6 months 
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INCLUSION CRITERIA 
1. Confirmed cases of type 2 diabetes mellitus 
2. Non diabetic controls without coronary artery disease  
EXCLUSION CRITERIA 
1. Patients on antiplatelet drugs such as aspirin and clopidogrel. 
2. Patients with abnormal platelet counts (thrombocytosis or 
thrombocytopenia) 
3. Type 1 diabetes mellitus patients 
4. Type 2 diabetes mellitus with macrovascular complications 
5. Diabetes complicating pregnancy 
6. Conditions causing transient urinary albumin excretion such as 
infection, heart failure, exercise and uncontrolled hypertension  
SAMPLE SIZE 
 A total of 140 patients which includes 90 diabetics and 50 controls. 
Healthy subjects who attended routine master health check ups were taken as 
control group 
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METHOD OF DATA COLLECTION 
 All the patients involved in the study are subjected to following 
parameters.  
1. History of patient  
2. General examination 
3. Systemic examination 
4. Laboratory investigations 
5. Electrocardiogram  
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METHODOLOGY 
HISTORY  
 A detailed history on diabetes and other comorbid illness were 
collected 
The history includes  
Age  
Sex 
Duration of diabetes 
History of chestpain, claudication pain and stroke 
History of blurring of vision 
History of comorbid illness such as hypertension 
Treatment history 
History of smoking and alcohol, if present the details of that 
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GENERAL EXAMINATION 
 The following parameters were assessed in all subject 
1. BMI based on weight and height using the formula 
weight/height in meter square 
2. Blood pressure was measured in the right arm with the patient in 
sitting position 
3. Other general examination was done 
SYSTEMIC EXAMINATION 
 The following systems were examined to detect any complications of 
diabetes 
CARDIOVASCULAR  
RESPIRATORY 
CENTRAL NERVOUS SYSTEM 
ABDOMEN 
LABORATORY INVESTIGATIONS 
 All the patients were subjected to the following investigations 
• Mean platelet volume 
• Urine albumin creatinine ratio 
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• Fasting blood glucose 
• Post prandial blood glucose 
• Glycosated haemoglobin levels(HbA1c) 
• Platelet count 
• Total cholesterol 
• Haemoglobin 
• Serum creatinine 
Mean platelet volume is measured by an automatic blood counter using 
venous blood samples which were taken in a test tube mixed with EDTA and 
tested within 1 hour of collection. HbA1c was measured using automated 
high performance liquid chromatography.  
 Serum glucose was measured by hexokinase enzymatic method. 
Albuminuria is measured by early morning urine albumin creatinine ratio. 
The diabetic patients are subdivided into three groups based on albuminuria 
levels 
• A1 (<30 mg/gm)  -  normoalbuminuria 
• A2(30-300 mg/gm) - high albuminuria 
• A3(>300mg/gm) – very high albuminuria 
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Mean platelet volume is assessed and compared in the above groups. Then 
based on HbA1c levels patient is again subdivided into (according to ADA 
criteria) 
• HbA1c ≤ 6.5 % 
• HbA1c > 6.5% 
 Again mean platelet volume is compared in the above mentioned 
groups thereby assessing its relation with glycaemic status of the patient.  
 
ANALYSIS PLAN 
 Statistical analysis was done using SPSS software version 17.0 
 
SPONSORSHIP 
 No 
CONFLICT OF INTEREST 
 None  
 
 
 
 
 
  
 
OBSERVATION  
AND  
RESULTS 
  
 OBSERVATION AND RESULTS
 A total number of 140 patients participated in our study that includes 
90 (64 %) type 2 diabetes mellitus patients and 50 (36%) age matched 
healthy controls.  Among them 88
females. They are distributed in age group of 40 to 70 years. 
DISTRIBUTION OF
 Our study includes 140 subjects among which 90 (64%) are type 2 
diabetes mellitus patients and 50 controls. 
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 (63 %) are males and 52 (37%) are 
 
 
FIGURE 1 
 PATIENTS IN OUR STUDY
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 SEX WISE DISTRIBUTION OF 
 
 
 In our diabetes group, 55 patients(61%) are males and 35 
patients(39%) are females
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FIGURE 2 
DIABETES PATIENTS
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FIGURE 3 
AGE WISE DISTRIBUTION OF DIABETES PATIENTS 
 
 
 
 In our study group 29% belongs to the age group 40-50, 67 % belongs 
to age group 51-60 and 4% belongs to more than 60 age group. 
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TABLE 1 
COMPARISON OF VARIOUS PARAMETERS BETWEEN THE 
DIABETIC AND NONDIABETIC CONTROLS 
Independent sample t test 
 
 
Control DM 
P value 
 
 
Mean SD Mean SD 
 
Age 52.58 4.26 51.93 4.51 0.409 
 
Duration of DM N/A N/A 5.57 1.98 N/A 
 
BMI 26.48 1.36 30.99 2.42 
<0.000
1 
 
MPV 7.93 0.24 8.8 0.36 
<0.000
1 
 
Urine albumin 
creatinine ratio 
N/A N/A 213.48 
189.2
7 N/A 
 
Platelet 3.8 0.48 3.59 0.43 0.009 
 
Hb 14.68 14.12 12.37 0.77 0.124 
 
Total cholesterol 180.54 18.99 
216.8
6 54.77 
<0.000
1 
 
Serum Creatinine 1.2 0.34 1.46 0.29 
<0.000
1 
 
FBS 89.6 9.73 
171.3
5 53.02 
<0.000
1 
 
PPBS 129.68 9.75 
248.5
1 84.81 
<0.000
1 
MPV was significantly higher (8.8± 0.36) in the diabetes patients when 
compared to control(7.93± 0.24) group and is stastically significant 
(p<0.0001) by independent sample t test. 
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The mean BMI in control group (26.48±1.36) was also lower than the 
diabetes group (30.99±2.42) and also stastically significant. 
The mean fasting blood sugar and post prandial blood sugar in the 
control group was (89.6± 9.73) and (129.68±9.75) while in the diabetes group 
it was (171.35± 53.02) and (248.51±84.51) respectively. 
The mean total cholesterol level in control group was (180.54±18.99) 
while in the diabetes group it was (216.86±54.77) 
The mean age of patients in control group was (52.58±4.26) while in 
the diabetes group it was (51.93±4.51) 
The mean platelet count in diabetes was (3.59± 0.43) while in the 
control group it was (3.8±0.48) 
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FIGURE 4 
CORRELATION OF MEAN PLATELET VOLUME WITH BMI 
 
 
 Mean platelet volume shows a positive correlation (p value – 0.042) 
with BMI in our study. The correlation coefficient calculated by Pearson 
correlation coefficient shows only weak correlation (0.215) 
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FIGURE 5 
MPV IN CONTROLS AND 
DIABETES PATIENTS 
(8.8± 0.36) 
(7.93± 0.24)  and independent sample test shows 
( p <0.0001) 
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 CORRELATION OF MPV ACROSS VARYING LEVELS OF 
ALBUMINURIA IN DIABETES PATIENTS
 
 The mean MPV in A1 group is (8.45± 0.19) which was lower than 
A2(8.87± 0.37). both groups were lower than A3 (8.99±
significance exists between A1 
and A3 does not show any statistical significance by independent t test.
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FIGURE 6 
and other two groups. (p <0.0001)  but A2 
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FIGURE 7 
CORRELATION OF MPV WITH FBS 
 
 There is no significant correlation between MPV and Fasting blood 
sugar (p value- 0.236) in diabetes patientsevaen though MPV is slightly 
higher in patients with FBS more than 110. 
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FIGURE 8 
CORRELATION OF MPV WITH PPBS 
 
 
 
 In diabetes patients with postprandial blood sugar more than 200 MPV 
is slightly on the higher side but still not statistically significant (p- 0.124) 
 
 
 
 
 
 
8.75
8.83
7.8
8
8.2
8.4
8.6
8.8
9
9.2
9.4
PPBS <200 PPBS >200
A
x
is
 T
it
le
Axis Title
PPBS
71 
 
FIGURE 9 
CORRELATION OF MPV WITH DURATION OF DIABETES 
 
 
There is no correlation between MPV with duration of diabetes 
(p – 0.648) 
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FIGURE 10 
CORRELATION OF MPV WITH TOTAL CHOLESTROL 
 
 MPV does not show any statistical significance with cholesterol level 
(p -0.402) 
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FIGURE 11 
CORRELATION OF MPV WITH PLATELET COUNT 
 
 We grouped the patient according to platelet count into five groups. 
MPV does not show any significant correlation (p -0.122) 
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FIGURE 12 
CORRELATION OF MPV WITH HB 
 
 
 There is no signicant correlation between MPV and haemoglobin 
levels. (p- 0.688) 
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FIGURE 13 
CORRELATION OF MPV WITH AGE OF DIABETES 
 
 
 
 There is no significant correlation exists between age and MPV in 
diabetes patients. (p- 0.069) 
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FIGURE 14 
CORRELATION OF MPV WITH GENDER 
 
 
 
 There is no significant correlation exists between diabetes and gender 
of the diabetes patients. (p -0.677) even though MPV is slightly higher in 
males when compared to females. 
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TABLE 2 
CORRELATION OF MPV IN DIABETES PATIENTS  
AND CONTROLS 
  MPV     
 
 
  Mean SD P value 
 
 
Control 7.93 0.24 <0.0001 
Independent 
sample t 
Test 
DM 8.8 0.36   
 
 
 
CORRELATION OF MPV ACROSS VARYING LEVELS OF 
ALBUMINURIA IN DIABETES PATIENTS 
MPV 
 
 
Mean SD P value 
 
One way Anova 
A1 8.45 0.19 
 
 
A2 8.87 0.37 <0.0001 
Post hoc test  
Bonferroni 
A3 8.99 0.27 <0.0001 
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CORRELATION OF MPV WITH HbA1c 
 
MPV 
Correlation 
coefficient P value 
HbA1c 0.145 0.174 Pearson correlation test 
 
CORRELATION OF MPV WITH VARIOUS PARAMETERS IN 
DIABETES PATIENTS 
Correlation 
coefficient P value 
 
 
Age -0.193 0.069 
Gender -0.045 0.677 
 
 
BMI 0.215 0.042 
 
 
Duration of DM -0.049 0.648 
 
 
Urine albumin creatinine 
ratio 0.403 <0.0001 
 
 
Platelet count 0.228 0.122 
Pearson 
correlation test 
Hemoglobin -0.043 0.688 
 
 
HbA1C 0.145 0.174 
 
 
Total cholesterol 0.089 0.402 
 
 
Serum Creatininine 0.155 0.145 
 
 
Fasting Blood Sugar 0.126 0.236 
 
 
Post Prandial Blood 
Sugar 0.226 0.124 
 
 
 
 
    
 
  
 
 
DISCUSSION 
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DISCUSSION 
 Once the platelets gets activated mean platelet volume tends to 
increase and also changes its disc shape into swollen spheres. Larger platelets 
have tendency to be more adhesive and aggregative then the smaller ones. 
They also produce larger amounts of prothrombotic factors.(43,44,45) This 
increase in mpv, aggregative capacity and large amounts of vasoactive 
molecule production is previously documented(45,46,47) 
 
 The mechanisms causing this has not been clearly defined yet there are 
theories which suggests that this increase in MPV  may be either due to 
osmotic swelling of megakaryocytes(48) or due to the effect of insulin which 
forces the platelet to change its structure(49) another postulation is that there 
will be increased platelet turnover and so the presence of younger 
megakaryocytes.(50) 
 
High albuminuria (previously microalbuminuria) is one of the earliest 
indicator of diabetic nephropathy. In our study we aimed at comparing mean 
platelet volume in controls and diabetics. Also we correlated MPV with 
various levels of albuminuria and HbA1c levels. 
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Our study shows that MPV was significantly higher in diabetes 
patients than controls. This was similar to previous studies.(51-53) In the 
diabetes patients  it was significantly higher in patient with group A2 i.ehigh 
albuminuria (previously called microalbuminuria) and group A3 i.every high 
albuminuria (previously called macroalbuminuria) when compared to patients 
with group A1 i.enormoalbuminuria. Some studies shows higher MPV in 
patients with microalbuminuria when compared to normoalbumiuria.(46,54,55) 
 
Some other studies fails to show this coorelation of MPV with 
albuminuria levels(45,56,57)This differences may be due to variations in size of 
the sample, type of anticoagulation used and other methodological variations 
such as fasting or fed state. Our study also implies that there is no much 
difference between group A2 (high albuminuria) and group A3(very high 
albuminuria) even though both groups have increased MPV. 
 
Unubol, Ayhan, Guney et al showed a significant positive relationship 
between mean platelet volume and microalbuminuria. Lutfullahcakir, 
GulaliAktas et al showed that mean platelet volume increases in type 2 
diabetes mellitus independent of HbA1c levels(71) 
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In our study there is no correlation between MPV and HbA1c levels. 
Various studies has been done which shows the same results(58,59,60,61,62-67) 
some studies suggests a positive correlation between MPV and HbA1c 
levels(51,53,61) and also states improvement in glycaemic control leads to 
decrease in MPV(53,60)kodiatte et al 2012 showed MPV is increased in 
patients with diabetes and had a positive correlation with fasting blood sugar, 
post prandial blood sugar and HbA1c levels(68) 
 
Also our study does not show any correlation of MPV with gender and 
duration of diabetes which is same as previous studies(58,63) This suggests the 
fact once vascular damage starts it will be constant and continues for the 
duration of disease independent of both duration and glycaemic control. 
 
Coban et al states MPV was found to have a significant correlation 
with BMI.(69) It also proves that implementing diet treatment will reduce the 
MPV(70) Our study also  shows a significant positive  correlation of MPV 
with BMI. Many previous studies suggests a conflicting results with MPV 
and BMI(58,48) We need to do larger studies with more patients to find the 
correlation. 
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Study done by turgutalp et al showed significant positive correlation of 
MPV with serum creatinine and negative correlation with GFR in diabetic 
nephropathy patients(55) Another study by barbek et al showed that MPV was 
higher in patients with low creatinine clearance(45) Our study shows no 
correlation between MPV and creatinine. This was explained by the fact we 
excluded patient with low GFR. 
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CONCLUSIONS 
Mean platelet volume is significantly higher in diabetes mellitus 
patients than healthy controls. 
In diabetes mellitus patients, Mean platelet volume is significantly 
higher in those with high albuminuria (previously microalbuminuria) and 
very high albuminuria (previously macroalbuminuria) when compared with 
patients having normoalbuminuria. 
It suggests platelet may have a role in causing the vascular 
complications of diabetes particularly diabetic nephropathy. Mean platelet 
volume is a simple, easy and affordable investigation. In our study there is a 
positive correlation exists between MPV and BMI. 
Also our study suggests no correlation of mean platelet volume with 
HbA1c, fasting blood sugar, postprandial blood sugar, serum creatinine, total 
cholesterol, duration of diabetes, age and sex. Further larger studies are 
needed to show its correlation in the future. 
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LIMITATIONS 
 The presence and absence of other diabetic complications was not 
analysed in the study.  
 The study includes only moderate size sample 
 Effects of the medications such as insulin and oral antihyperglycaemic 
on MPV was not included in this study. 
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ANNEXURES 
  
PROFORMA 
MEAN PLATELET VOLUME IN PATIENTS WITH TYPE 2 DIABETES 
MELLITUS AND ITS CORRELATION ACROSS VARYING  
LEVELS OF ALBUMINURIA AND HBA1C LEVELS 
 
Name    :     Patient  ID  : 
Age      :  
Sex     :  
Duration of diabetes :  
H/O chest pain  : 
H/O claudication pain : 
H/O blurring of vision : 
H/O chest pain  : 
Past H/O    : h/o  CAD , CVA , HTN 
Personal H/O   : h/o   smoking , alcohol  
 
 
 
General examination  : 
 BMI 
 BP 
 Pallor 
Systemic  examination : 
 CVS 
 RS 
 ABDOMEN 
 CNS 
Investigations  : 
 Mean platelet volume 
 Albumin creatinine ratio 
 Fasting blood glucose 
 Post prandial blood sugar 
 HBA1C 
 Platelet count 
 Total cholesterol 
 Haemoglobin 
 Sr creatinine 
  
  
 
TURNITIN PLAGIARISM SCREENSHOT
 
 
 
 
 
 
 
 
 
 
 
  
 
  
INFORMATION SHEET 
We are conducting a study on “MEAN PLATELET VOLUME IN 
PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ITS 
CORRELATION ACROSS VARYING LEVELS OF ALBUMINURIA AND 
HBA1C LEVELS” among patients attending Rajiv Gandhi Government General 
Hospital, Chennai and for that your specimen may be valuable to us. 
           The purpose of this study is to assess the mean platelet volume in type 2 
Diabetes Mellitus and correlate across varying levels of albuminuria and HbA1C 
levels. 
 
The following tests: 
1. Mean Platelet volume 2. Urine Albumin Creatinine ratio 3. Fasting blood 
sugar 
4. Post Prandial blood sugar  5. HBA1C levels are to be performed.   
 
 We are selecting certain cases and if you are found eligible, we may be using 
your blood samples to do certain tests which in any way do not affect your final 
report or management. 
The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the research, 
no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result in 
any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in the 
management or treatment. 
 
Signature of Investigator     Signature of Participant 
 
Date: 
Place:   
   
PATIENT CONSENT FORM 
Study Detail : “MEAN PLATELET VOLUME IN PATIENTS WITH 
TYPE 2 DIABETES MELLITUS AND ITS 
CORRELATION ACROSS VARYING LEVELS OF 
ALBUMINURIA AND HBA1C LEVELS” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and doubts 
have been answered to my complete satisfaction. 
❏ 
b) I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being 
affected. 
❏ 
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of current 
study and any further research that may be conducted in relation to it, even if 
I withdraw from the study I agree to this access. However, I understand that 
my identity will not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from this study. 
❏ 
d) I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. 
❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. 
❏ 
 
Signature thumb impression    Signature of Investigator 
 
Patient’s Name and Address    Study Investigator’s Name 
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1 62 Male 31.2 8 8.5 20 A1 2.87 13.8 6.4 212 1.2 118 148 
2 59 Male 21.6 6 8.4 22 A1 2.73 12.7 7.2 190 0.8 142 198 
3 60 Female 30.1 8 8.3 12 A1 3.12 13.4 8.2 234 1.5 234 298 
4 54 Male 28.2 5 8.5 13 A1 2.87 11.9 5.5 200 1.3 102 145 
5 51 Male 29.2 6 8.7 23 A1 2.76 11.4 6.9 224 1.1 168 198 
6 58 Female 32.4 7 8.6 15 A1 3.42 12.9 7.2 286 1.7 168 254 
7 56 Female 26.3 6 8.4 21 A1 2.97 13.9 6.4 234 1.1 103 143 
8 42 Male 32.4 5 8.4 22 A1 4.23 12.4 7.3 223 1.6 198 254 
9 54 Male 34.1 4 8.2 12 A1 3.93 13.4 8.4 254 1.5 204 267 
10 56 Female 34.4 3 8.3 14 A1 3.76 11.9 6.3 190 1.3 121 145 
11 65 Male 27.8 6 8.5 23 A1 4.21 13.6 7.6 234 1.5 198 265 
12 59 Female 32.1 5 8.6 11 A1 3.65 11.6 7.4 222 1.2 197 299 
13 58 Male 30.7 6 8.5 15 A1 3.87 12.7 8.3 187 1.7 234 334 
14 54 Female 31.4 7 8.4 13 A1 3.98 13.7 5.5 165 1.1 97 132 
15 49 Male 32.1 8 8.5 11 A1 3.76 12.7 6.1 187 1.3 113 143 
16 47 Female 34.4 11 8.7 16 A1 3.76 11.3 6.4 198 1.3 102 132 
17 54 Male 29.7 4 8.9 13 A1 3.54 13.7 7.3 143 0.8 154 198 
18 61 Female 28.7 3 7.9 12 A1 3.43 11.2 7.3 203 0.6 176 232 
19 46 Male 27.7 5 8.3 11 A1 3.31 12.6 6.3 165 1.3 112 143 
20 53 Male 29.4 6 8.4 15 A1 3.34 11.4 6.1 187 1.7 87 132 
21 52 Male 29.3 7 8.4 17 A1 3.42 12.7 7.7 234 1.9 198 265 
22 51 Male 30.4 6 8.5 18 A1 3.11 13.4 8.1 222 1.5 232 398 
23 55 Male 30.7 6 8.6 22 A1 3.17 13.1 6.6 165 1.3 113 175 
24 56 Female 30.8 5 8.5 15 A1 4.12 11.9 6.2 187 1.2 117 154 
25 46 Male 32.1 4 8.9 45 A2 3.87 13.7 7.3 132 1.7 187 232 
26 55 Male 30.5 7 9.2 53 A2 4.43 12.5 7.1 165 1.4 198 265 
27 53 Female 33.2 4 9.1 56 A2 3.65 11.8 6.2 187 1.3 112 176 
28 54 Male 34.7 5 8.9 54 A2 3.45 12.4 7.1 203 1.6 198 287 
29 51 Female 34.1 6 8.5 43 A2 3.56 11.5 7.7 265 1.5 212 324 
30 64 Male 32.1 5 9.3 109 A2 4.76 12.7 8.2 235 1.3 287 398 
31 52 Male 36.3 6 9.6 232 A2 4.86 13.7 7.2 198 1.3 187 254 
32 55 Male 29.6 4 8.3 134 A2 3.36 13.2 6.1 176 1.2 197 236 
33 49 Female 28.7 2 8.6 57 A2 3.65 11.1 6.3 186 1.7 132 165 
34 47 Male 31.2 1 8.9 87 A2 4.43 13.8 7.2 302 1.4 199 236 
35 43 Male 28.7 7 9 68 A2 4.23 12.3 7.1 202 1.9 197 287 
36 52 Female 29.6 6 9.2 90 A2 4.12 11.5 7.4 243 1.3 202 298 
37 53 Male 29.9 8 9 112 A2 4.13 12.3 8.1 212 1.9 256 387 
38 54 Female 28.2 9 9.1 243 A2 4.12 12.2 6.4 176 1.3 154 219 
39 52 Male 28.4 12 8.5 256 A2 3.87 11.7 7.1 198 1.2 198 287 
40 51 Female 32.3 6 8.9 187 A2 3.12 11.3 7.2 234 1.7 232 287 
41 49 Female 32.6 5 8.8 115 A2 3.32 11.9 6.2 154 1.2 112 165 
42 54 Female 32.7 6 9 156 A2 3.34 11.3 6.1 176 1.4 86 143 
43 55 Female 32.6 4 9.4 143 A2 3.45 11.4 8.2 165 1.5 123 198 
44 54 Female 32.6 6 9.2 254 A2 3.65 11.6 7.2 154 1.2 135 234 
45 51 Male 32.8 7 9.2 232 A2 3.54 12.6 7.4 176 1.7 232 342 
46 43 Male 31.7 5 9.4 124 A2 3.23 12.5 7.1 187 1.3 211 323 
47 48 Male 32.9 7 9.2 187 A2 3.21 13.4 7.2 165 1.2 236 343 
48 49 Male 32.4 5 9.2 169 A2 3.53 13.3 8.1 176 1.8 276 387 
49 52 Female 32.5 9 9 199 A2 3.32 12.5 6.4 176 1.3 132 176 
50 51 Male 32.9 2 8.7 232 A2 3.73 13.4 6.1 187 1.2 84 154 
51 52 Male 32.6 3 8.8 145 A2 3.21 12.8 6.3 198 1.3 102 143 
52 55 Male 32.4 4 8.8 87 A2 3.31 13.4 7.3 345 1.3 165 298 
53 53 Male 37 7 8.9 76 A2 3.26 12.7 7.5 365 1.3 212 356 
54 53 Male 31.2 6 8.1 112 A2 3.14 12.6 7.3 234 1.8 213 298 
55 52 Female 29.6 5 8.5 169 A2 3.12 12.4 6.1 198 1.4 102 143 
56 51 Female 25.7 3 8.6 238 A2 3.87 11.2 6.9 176 1.3 121 165 
57 51 Male 28.7 5 8.7 234 A2 3.12 12.4 7.1 143 1.9 222 298 
58 48 Female 30.8 6 8.1 221 A2 3.11 11.2 6.6 187 1.3 187 254 
59 49 Male 29.4 9 8 143 A2 4.34 12.5 6.7 167 1.2 143 198 
60 54 Male 28.9 4 8.9 150 A2 4.32 12.2 7.7 198 1.3 198 267 
61 52 Male 31.2 4 9.1 434 A3 4.35 11.9 7.2 178 1.5 212 302 
62 45 Female 33.3 5 9.2 387 A3 3.98 11.5 6.2 167 1.3 112 165 
63 49 Male 31.9 6 8.9 543 A3 3.76 12.5 7.4 154 1.8 198 234 
64 51 Female 31.7 5 8.8 487 A3 3.76 12.7 7.2 178 1.7 178 287 
65 53 Male 31 3 8.8 587 A3 3.76 12.8 7.7 232 1.1 198 343 
66 52 Female 32.9 2 9.1 345 A3 3.54 12.2 8.2 254 0.9 276 443 
67 55 Male 29.8 4 9.2 462 A3 3.56 11.9 6.4 345 1.6 123 187 
68 53 Male 34.5 5 8.8 543 A3 3.78 11.8 5.9 365 1.7 89 118 
69 49 Male 29.3 6 9.2 376 A3 3.76 11.7 6 234 1.8 98 123 
70 42 Female 33.1 8 8.9 432 A3 3.43 11.5 7.1 231 1.9 187 285 
71 45 Female 32.9 7 9 387 A3 3.36 12.3 7.5 187 1.4 202 298 
72 54 Male 27.8 9 9.1 568 A3 4.11 12.5 7.4 235 1.7 245 324 
73 53 Male 28.7 8 8.3 678 A3 3.98 12.4 7.2 265 1.9 254 302 
74 52 Male 27.6 6 9.1 365 A3 3.26 11.9 7.1 178 1.8 198 287 
75 51 Female 32.4 7 9 443 A3 3.58 12.8 8.2 243 1.7 254 443 
76 49 Female 33.7 8 8.6 467 A3 3.42 11.7 7.8 187 1.5 276 387 
77 48 Male 28.7 4 8.7 543 A3 3.23 11.5 6.5 222 1.4 123 187 
78 45 Male 32.1 2 8.9 442 A3 3.76 11.4 6.4 287 1.9 121 176 
79 54 Male 33.5 1 8.6 365 A3 3.43 12.7 6.9 302 2.1 145 187 
80 55 Female 33.7 5 8.7 387 A3 3.27 13.2 6.4 332 1.9 112 165 
81 53 Male 33.5 4 9.3 398 A3 3.18 12.9 6.5 187 1.2 105 156 
82 51 Female 33.2 4 9.2 421 A3 3.17 11.7 6.7 176 1.4 143 187 
83 46 Male 32.1 6 9 442 A3 3.15 13.2 7.7 176 1.3 187 342 
84 45 Female 29.4 5 8.9 467 A3 3.19 11.3 7.4 167 1.9 165 298 
85 47 Male 29.7 7 8.9 465 A3 3.45 12.9 7.9 298 1.8 197 387 
86 46 Female 29.4 6 9.1 441 A3 3.65 11.3 8.1 287 1.7 232 443 
87 55 Female 29.1 5 9.2 442 A3 3.76 11.2 7.5 323 1.9 197 287 
88 54 Male 29.3 6 9.7 324 A3 3.87 12.8 7.2 298 1.6 187 278 
89 51 Male 28.7 5 9.2 432 A3 3.36 12.7 7.1 345 1.5 167 305 
90 52 Male 28.3 6 9.3 543 A3 3.65 12.9 6.2 298 1.5 113 165 
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1 48 Male 29.5 
 
7.7 
  
3.12 11.5 
 
187 1.2 87 132 
2 49 Female 24.5 
 
8 
  
3.65 12.5 
 
134 0.9 78 143 
3 54 Male 23.6 
 
8.1 
  
3.54 14.3 
 
165 0.7 98 112 
4 55 Male 25.8 
 
7.9 
  
3.43 13.7 
 
204 1.4 102 140 
5 53 Male 26.4 
 
7.8 
  
4.32 12.9 
 
234 1.3 78 102 
6 51 Female 27.3 
 
7.5 
  
4.51 11.3 
 
127 1.1 102 132 
7 56 Male 28.4 
 
7.6 
  
2.95 12.5 
 
165 0.7 98 123 
8 55 Female 26 
 
7.7 
  
3.23 11.9 
 
187 0.9 87 132 
9 54 Male 25.4 
 
8.5 
  
3.43 12.8 
 
198 1 78 123 
10 49 Male 24.6 
 
8 
  
4.12 12.8 
 
165 1.2 65 112 
11 55 Male 26.2 
 
7.9 
  
3.65 11.9 
 
158 1.9 102 136 
12 52 Male 23.4 
 
7.7 
  
3.87 112.4 
 
176 0.7 78 102 
13 51 Male 27.8 
 
7.4 
  
4.12 13.9 
 
179 0.9 89 123 
14 57 Male 29.2 
 
7.9 
  
4.35 13.4 
 
187 1.2 98 132 
15 58 Female 28.7 
 
8 
  
4.76 11.5 
 
234 1.1 86 129 
16 48 Male 26.7 
 
8.1 
  
4.65 14.3 
 
176 1.5 79 124 
17 49 Male 29 
 
8.2 
  
4.53 13.2 
 
169 1.4 97 134 
18 47 Female 28.9 
 
8.2 
  
4.32 11.8 
 
176 1.7 99 132 
19 56 Male 27.6 
 
8.2 
  
4.31 13.2 
 
190 1.2 102 136 
20 51 Male 27.4 
 
8.1 
  
4.21 12.5 
 
204 1.1 78 103 
21 52 Female 27.5 
 
8 
  
3.78 12.3 
 
176 1.2 87 132 
22 53 Male 26.4 
 
7.9 
  
3.98 13.5 
 
187 1.4 98 138 
23 57 Male 25.7 
 
8.6 
  
3.65 13.1 
 
189 1.3 89 137 
24 58 Female 24.7 
 
7.8 
  
3.43 12.4 
 
167 1.2 76 129 
25 53 Male 25.8 
 
7.7 
  
3.65 13.6 
 
178 0.8 86 132 
26 54 Female 25.3 
 
8 
  
3.87 11.6 
 
165 0.7 97 127 
27 55 Male 26.4 
 
7.9 
  
3.21 13.2 
 
176 0.5 104 139 
28 57 Female 27.5 
 
7.6 
  
3.54 11.4 
 
168 0.7 95 137 
29 53 Female 26.7 
 
7.5 
  
3.65 12.2 
 
187 1.2 86 134 
30 52 Male 26.8 
 
7.6 
  
3.53 13.4 
 
169 1.3 76 123 
31 49 Male 26.8 
 
7.7 
  
3.65 13.7 
 
158 1.4 84 129 
32 47 Male 25.7 
 
7.9 
  
3.23 12.7 
 
178 1.5 83 132 
33 49 Male 24.9 
 
8 
  
3.56 12.5 
 
176 1.2 75 129 
34 46 Male 25.2 
 
7.9 
  
4.43 12.3 
 
167 0.7 96 138 
35 42 Male 25.7 
 
8.1 
  
4.23 12.7 
 
167 0.8 99 139 
36 44 Male 25.8 
 
8.2 
  
4.31 13.6 
 
187 1.3 96 137 
37 52 Female 25.3 
 
8.3 
  
3.76 12.3 
 
176 1.6 103 129 
38 58 Female 26.3 
 
8.1 
  
3.65 11.6 
 
169 1.3 96 127 
39 57 Male 26.2 
 
8 
  
3.34 11.6 
 
187 1.3 94 124 
40 59 Female 26.1 
 
8.1 
  
4.41 12.4 
 
197 1.8 93 126 
41 56 Male 27.2 
 
7.9 
  
4.46 13.2 
 
176 1.6 92 132 
42 47 Female 28.3 
 
7.6 
  
4.35 11.6 
 
187 1.5 98 135 
43 59 Male 27.5 
 
7.9 
  
4.31 12.5 
 
196 1.3 103 145 
44 60 Female 26.9 
 
7.8 
  
2.92 12.4 
 
187 1.2 87 132 
45 52 Male 25.4 
 
8 
  
3.12 13.6 
 
197 1.1 98 136 
46 48 Female 26.8 
 
8.1 
  
3.76 12.2 
 
186 1.7 86 146 
47 47 Female 25.6 
 
8.2 
  
3.54 11.7 
 
178 1.8 75 132 
48 52 Male 26.4 
 
8 
  
3.32 12.7 
 
178 1.9 86 126 
49 57 Male 26.2 
 
7.8 
  
3.57 13.2 
 
198 0.9 85 128 
50 56 Male 26.9 
 
7.9 
  
3.15 14.5 
 
205 0.8 76 132 
 
KEY TO MASTER CHART 
S.NO    :  serial number 
BMI    :  body mass index 
FBS    :  fasting blood sugar 
PPBS    :  post prandial blood sugar 
A1    : normo albuminuria (< 30 mg/gm of creatinine) 
A2    :  high albuminuria (30- 300 mg/gm of creatinine) 
A3    :  very high albuminuria (> 300 mg/gm of creatinine) 
TC    :  total cholesterol 
HB    :  haemoglobin 
PLT    :  platelet count  
HBA1C   :  glycated haemoglobin 
URINE ACR  : urine albumin creatinine ratio  
MPV    :  mean platelet volume  
M    :  male  
F    :  female  
 
